News
ECOR
6.70
+1.29%
0.09
electroCore to present at LD Micro Invitational XVI Conference
PUBT · 1d ago
Weekly Report: what happened at ECOR last week (0504-0508)?
Weekly Report · 1d ago
electroCore to present at LD Micro Invitational XVI Conference
PUBT · 4d ago
electroCore to present at LD Micro Invitational XVI conference
PUBT · 4d ago
Maxim Group Sticks to Their Buy Rating for Electrocore (ECOR)
TipRanks · 4d ago
Electrocore Earnings Call Highlights Growth Amid Losses
TipRanks · 4d ago
electroCore price target lowered to $19.85 from $22 at Ladenburg
TipRanks · 5d ago
Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Warby Parker (WRBY)
TipRanks · 5d ago
ElectroCore reaffirms 2026 revenue guidance of ~30% growth while targeting deeper VA utilization
Seeking Alpha · 5d ago
electroCore reports Q1 EPS (59c) vs. (47c) last year
TipRanks · 5d ago
electroCore backs FY26 revenue view up 30%
TipRanks · 5d ago
Earnings Scheduled For May 6, 2026
Benzinga · 6d ago
electroCore reiterates FY 2026 revenue guidance
Reuters · 6d ago
BRIEF-electroCore Q1 Net Income USD -5.271 Million
Reuters · 6d ago
Weekly Report: what happened at ECOR last week (0427-0501)?
Weekly Report · 05/04 09:05
electroCore to report first-quarter results after market close, host webinar
PUBT · 04/29 12:06
electroCore to present at Market Movers Investor Summit
PUBT · 04/28 12:15
Weekly Report: what happened at ECOR last week (0420-0424)?
Weekly Report · 04/27 09:05
Weekly Report: what happened at ECOR last week (0413-0417)?
Weekly Report · 04/20 09:04
Former ElectroCore Insider Makes Notable Exit From the Stock
TipRanks · 04/15 02:03
More
Webull provides a variety of real-time ECOR stock news. You can receive the latest news about Electrocore through multiple platforms. This information may help you make smarter investment decisions.
About ECOR
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.